Mon cancers helps tumor progression contributing to evasion from immune surveillance Kliqqi
1
Mon cancers helps tumor progression contributing to evasion from immune surveillance [39]. Our data suggest that TUSC2 is a potent suppressor of this key immunoreceptor (Table 3 and Fig. 3). Since blocking of CD274 is now actively pursued as a novel immunotherapy [40,41], we suggest that TUSC2 may also have important immunotherapeutic implications. Our study on the TUSC2 role in mesothelioma under